CA2371223A1 - 49 proteines secretees humaines - Google Patents

49 proteines secretees humaines Download PDF

Info

Publication number
CA2371223A1
CA2371223A1 CA002371223A CA2371223A CA2371223A1 CA 2371223 A1 CA2371223 A1 CA 2371223A1 CA 002371223 A CA002371223 A CA 002371223A CA 2371223 A CA2371223 A CA 2371223A CA 2371223 A1 CA2371223 A1 CA 2371223A1
Authority
CA
Canada
Prior art keywords
human
seq
sequence
polypeptide
soares
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002371223A
Other languages
English (en)
Inventor
Craig A. Rosen
Steven M. Ruben
George Komatsoulis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2371223A1 publication Critical patent/CA2371223A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des nouvelles protéines sécrétées humaines et des acides nucléiques isolées contenant les régions codantes des gènes codant pour lesdites protéines. Elle porte encore sur des vecteurs, sur des cellules hôtes, sur des anticorps et sur des méthodes de recombinaison pour la production de protéines sécrétées humaines. Elle se rapporte encore à des méthodes diagnostiques et thérapeutiques utiles pour le diagnostic et le traitement de maladies, de troubles et/ou d'états liés à ces nouvelles protéines sécrétées humaines.
CA002371223A 1999-04-09 2000-04-06 49 proteines secretees humaines Abandoned CA2371223A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12869799P 1999-04-09 1999-04-09
US60/128,697 1999-04-09
US17692900P 2000-01-20 2000-01-20
US60/176,929 2000-01-20
PCT/US2000/009067 WO2000061627A1 (fr) 1999-04-09 2000-04-06 49 proteines secretees humaines

Publications (1)

Publication Number Publication Date
CA2371223A1 true CA2371223A1 (fr) 2000-10-19

Family

ID=26826857

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002371223A Abandoned CA2371223A1 (fr) 1999-04-09 2000-04-06 49 proteines secretees humaines

Country Status (5)

Country Link
EP (1) EP1173479A4 (fr)
JP (1) JP2003500019A (fr)
AU (1) AU4074300A (fr)
CA (1) CA2371223A1 (fr)
WO (1) WO2000061627A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1213352A1 (fr) * 2000-12-07 2002-06-12 Aventis Pharma S.A. Acides nucléiques des gènes humains abca5, abca6, abca9 et abca10, des vecteurs les contenant et leurs utilisations
EP3280431B1 (fr) * 2015-04-08 2023-11-08 University of Georgia Research Foundation, Inc. Dislocation du complexe de la protéine wave3 pour supprimer l'invasion et la métastase

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654139A (en) * 1994-09-21 1997-08-05 The United States Of America As Represented By The Department Of Health And Human Services Allelic variation of the serotonin 5HT2c receptor

Also Published As

Publication number Publication date
WO2000061627A1 (fr) 2000-10-19
EP1173479A4 (fr) 2002-11-20
JP2003500019A (ja) 2003-01-07
EP1173479A1 (fr) 2002-01-23
AU4074300A (en) 2000-11-14

Similar Documents

Publication Publication Date Title
CA2385475A1 (fr) 18 proteines secretees humaines
CA2382185A1 (fr) 48 proteines secretees humaines
CA2383041A1 (fr) 49 proteines secretees humaines
CA2370489A1 (fr) 49 proteines humaines secretees
CA2368927A1 (fr) Quarante-cinq proteines humaines secretees
CA2387696A1 (fr) 48 proteines humaines secretees
CA2365223A1 (fr) Proteines humaines secretees (46)
CA2370767A1 (fr) 49 proteines humaines secretees
CA2368281A1 (fr) 50 proteines humaines secretees
CA2368467A1 (fr) 50 proteines humaines secretees
CA2365522A1 (fr) 48 proteines secretees humaines
CA2368302A1 (fr) 49 proteines secretees par un etre humain
CA2364635A1 (fr) 47 proteines humaines secretees
CA2370441A1 (fr) 50 proteines humaines secretees
CA2371172A1 (fr) 50 proteines humaines secretees
CA2365247A1 (fr) Proteines humaines secretees (49)
CA2364650A1 (fr) Proteines humaines secretees (50)
CA2382743A1 (fr) 48 proteines secretees humaines
CA2370189A1 (fr) 48 proteines secretees humaines
CA2371223A1 (fr) 49 proteines secretees humaines
CA2365905A1 (fr) 48 proteines humaines secretees
CA2368210A1 (fr) Cinquante proteines humaines secretees
CA2368916A1 (fr) 49 proteines humaines secretees
CA2368700A1 (fr) Quarante-neuf proteines humaines secretees
CA2367620A1 (fr) Proteines humaines secretees (47)

Legal Events

Date Code Title Description
FZDE Discontinued